Intellia reports an 89% reduction in hereditary angioedema attacks with lonvo-z, alongside sustained kallikrein suppression and prophylaxis-free outcomes.
Written By: Anshu Gupta, PharmD
Reviewed By: Pharmacally Editorial Team
Intellia Therapeutics announced additional clinical and patient-reported findings for lonvoguran ziclumeran (lonvo-z; formerly NTLA-2002) on November 12, 2026, across seven presentations scheduled for the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting (November 12–16, 2026) in Phoenix, Arizona. The findings include data from its Phase 1/2 study (NCT05120830) and Phase 3 HAELO study (NCT06634420), providing further evidence of sustained disease control following a single administration of the investigational gene-editing therapy.
An integrated analysis of 93 patients receiving a single 50 mg dose across both programmes demonstrated an 89% overall reduction in hereditary angioedema (HAE) attack rate from baseline through follow-up extending up to four years. At the latest follow-up, all patients were free from long-term prophylaxis (LTP), while 97% had never initiated LTP following treatment.
Phase 3 Findings Extend Evidence Beyond Previous Prophylaxis
Among 35 Phase 3 HAELO participants who were receiving LTP at study entry and randomized to lonvo-z, the mean monthly HAE attack rate decreased by 81% during the efficacy observation period compared with their previous LTP experience. Additionally, 63% achieved complete disease control, more than tripling the attack-free rate observed during their previous prophylactic treatment. Consistent reductions in attack rates favouring lonvo-z over placebo were observed across prespecified subgroups, irrespective of disease severity or previous LTP treatment.
The distinction between these findings and the integrated analysis is important. The 81% reduction reflects a specific subgroup comparison against previous prophylactic treatment, whereas the 89% reduction represents the pooled clinical population’s change from baseline.
The Phase 3 HAELO trial was a randomized, double-blind, placebo-controlled study involving 80 participants, with 52 assigned to lonvo-z and 28 to placebo. Its previously reported primary efficacy findings established the treatment’s benefit against placebo. The additional subgroup analysis provides further information on outcomes among patients transitioning from existing prophylactic treatment.
Sustained Biological Activity and Prophylaxis-Free Outcomes
Long-term Phase 1/2 findings demonstrated sustained reductions in plasma kallikrein following a single 50 mg administration. Mean plasma kallikrein levels decreased by 84% at four weeks, with reductions maintained through follow-up extending up to four years. These biomarker findings support the intended mechanism of KLKB1 gene inactivation, reducing plasma kallikrein production and downstream activity of the kallikrein-kinin pathway responsible for bradykinin-mediated swelling attacks.
Among 32 Phase 1/2 participants, at least 90% remained attack-free during each assessed month after the first year of treatment. All participants were free from LTP at the data cutoff. The estimated probability of beginning an interval exceeding six months without attacks or LTP increased from 81% at six months to 93% at 24 months after treatment.
Together, these findings suggest that the biological effects of lonvo-z can translate into prolonged periods without attacks or conventional prophylactic treatment, although individual follow-up durations varied.
Patient-Reported Outcomes and Quality of Life
Interviews involving 23 Phase 1/2 participants, with a median follow-up of 2.4 years after infusion, showed that all reported well-controlled HAE following treatment, compared with 48% before receiving lonvo-z. Additionally, 86% described a change in their understanding of disease control, moving from symptom management and medication dependence towards fewer attacks and reduced treatment burden. Overall, 22 participants (96%) described lonvo-z as an optimal HAE therapy. These findings provide qualitative insight into patients’ experiences rather than a comparative clinical efficacy measurement.
The Phase 3 HAELO study also met its key secondary endpoint for improvement in the Angioedema Quality of Life (AE-QoL) total score at Week 28. Patients receiving lonvo-z experienced a mean 23.5-point reduction from baseline, compared with a 6.5-point reduction with placebo. The improvement with lonvo-z substantially exceeded the established six-point threshold for a clinically important difference, with benefits observed across all four AE-QoL domains and sustained over time.
Treatment Gaps and Safety Findings
A separate US claims database analysis involving 538 patients receiving LTP over a median of 1.2 years found that almost 40% were non-adherent. HAE attack rates were similar between adherent and non-adherent groups, highlighting the continuing treatment burden and occurrence of breakthrough attacks despite preventive therapy.
Current HAE prevention strategies can require lifelong medication, including intravenous or subcutaneous administration as frequently as twice weekly or daily oral treatment. Lonvo-z is being investigated as an alternative approach that could reduce dependence on repeated prophylactic dosing.
Across the integrated clinical analysis, the most frequently reported treatment-emergent adverse events, occurring in more than 15% of patients, included infusion-related reactions, headache, fatigue and nasopharyngitis. No new long-term safety risks were identified. In the Phase 3 HAELO study, all treatment-emergent adverse events in the lonvo-z arm were mild or moderate, with no serious adverse events reported.
Mechanism of Action and Regulatory Progress
Lonvo-z is an investigational in vivo CRISPR/Cas9 gene-editing therapy designed to inactivate the KLKB1 gene through a single intravenous administration. By reducing plasma kallikrein production, the treatment aims to suppress bradykinin-mediated swelling attacks at their biological source.
The therapy has received five regulatory designations, including FDA Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations, the UK Medicines and Healthcare products Regulatory Agency’s Innovation Passport, European Medicines Agency PRIME designation and European Commission Orphan Drug Designation.
In September 2026, the US Food and Drug Administration accepted Intellia’s Biologics License Application (BLA) for lonvo-z and granted Priority Review, with a target Prescription Drug User Fee Act (PDUFA) action date of March 10, 2027.
Clinical Interpretation
The additional findings strengthen the clinical evidence supporting lonvo-z as a potential long-term treatment approach for HAE. The integrated 89% reduction in attacks, sustained kallikrein suppression and prophylaxis-free outcomes suggest that targeting KLKB1 through a single gene-editing intervention may address an important limitation of conventional preventive treatment: continued dependence on repeated medication administration.
The improvements in quality of life and patient-reported disease control further indicate that the potential benefit extends beyond attack reduction to treatment burden. However, follow-up durations vary across the clinical populations, and the available evidence does not establish lifelong clinical benefit or exclude uncommon long-term risks. Continued safety monitoring will be particularly important given the intended permanent genetic modification. The FDA’s decision will ultimately depend on its assessment of the complete clinical and safety evidence.
References
Intellia Therapeutics. Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026. November 12, 2026.
ClinicalTrials.gov. Phase 1/2 Study of NTLA-2002 in Adults With Hereditary Angioedema. NCT05120830.
ClinicalTrials.gov. HAELO: A Phase 3 Study of NTLA-2002 in Participants With Hereditary Angioedema. NCT06634420.
About the Writer
Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.